Abramson Cancer Center at Penn Medicine: Melanoma trials
The registry lists 18 Melanoma studies with Abramson Cancer Center at Penn Medicine as lead sponsor. 1 are open to participants now and 6 have results posted.
Early Phase 1 2Phase 1 7Phase 2 8No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced MelanomaNot yet recruitingNCT07700121Early Phase 1
- Imaging FDG Flare in MelanomaCompletedNCT02791594Results posted
- A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced MelanomaCompletedNCT02434354Phase 1Results posted
- RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMACompletedNCT01497808Phase 1/2Results posted
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerCompletedNCT01037790Phase 2Results posted
- Study of Temzolomide and Gleevec in Advanced MelanomaTerminatedNCT00667953Phase 1/2Results posted
- Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00602576Phase 2Results posted
- Zr89 + PET Companion TrialActive, not recruitingNCT05279027Early Phase 1
- Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabActive, not recruitingNCT04013854Phase 2
- Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C MelanomaActive, not recruitingNCT03757689Phase 2
- Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaActive, not recruitingNCT03646617Phase 2
- Circulating Tumor Material in Colorectal Cancer and MelanomaCompletedNCT02907086
- Bio-marker Analysis Using Circulating Tumor Cells in Patients With MelanomaWithdrawnNCT02828345
- Early FDG PET in MelanomaTerminatedNCT02716077Not applicable
- Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1
- Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedNCT02257424Phase 1/2
- A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedNCT01897116Phase 1
- Tremelimumab and CP-870,893 in Patients With Metastatic MelanomaCompletedNCT01103635Phase 1